A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain by Carayon, Kevin et al.
A cooperative and specific DNA-binding mode
of HIV-1 integrase depends on the nature of
the metallic cofactor and involves the
zinc-containing N-terminal domain
Kevin Carayon, Herve ´ Leh, Etienne Henry, Franc ¸oise Simon, Jean-Franc ¸ois Mouscadet
and Eric Deprez*
LBPA, CNRS, Ecole Normale Supe ´rieure de Cachan, 61 av. du Pre ´sident Wilson, 94235 Cachan, France
Received July 23, 2009; Revised and Accepted February 2, 2010
ABSTRACT
HIV-1 integrase catalyzes the insertion of the viral
genome into chromosomal DNA. We characterized
the structural determinants of the 30-processing
reaction specificity—the first reaction of the integra-
tion process—at the DNA-binding level. We found
that the integrase N-terminal domain, containing a
pseudo zinc-finger motif, plays a key role, at least
indirectly, in the formation of specific integrase–
DNA contacts. This motif mediates a cooperative
DNA binding of integrase that occurs only with the
cognate/viral DNA sequence and the physiologically
relevant Mg
2+ cofactor. The DNA-binding was
essentially non-cooperative with Mn
2+ or using
non-specific/random sequences, regardless of
the metallic cofactor. 2,20-Dithiobisbenzamide-1
induced zinc ejection from integrase by covalently
targeting the zinc-finger motif, and significantly
decreased the Hill coefficient of the Mg
2+-
mediated integrase–DNA interaction, without
affecting the overall affinity. Concomitantly,
2,20-dithiobisbenzamide-1 severely impaired
30-processing (IC50=11–15nM), suggesting that
zinc ejection primarily perturbs the nature of the
active integrase oligomer. A less specific and
weaker catalytic effect of 2,20-dithiobisbenzamide-1
is mediated by Cys 56 in the catalytic core and,
notably, accounts for the weaker inhibition of the
non-cooperative Mn
2+-dependent 30-processing.
Our data show that the cooperative DNA-binding
mode is strongly related to the sequence-
specific DNA-binding, and depends on the simulta-
neous presence of the Mg
2+ cofactor and the zinc
effector.
Integration of HIV-1 DNA into the host genome ensures
stable maintenance of the viral genome in the host
organism and, therefore, is a key process in the virus life
cycle. Integrase (IN) is responsible for two distinct, con-
secutive catalytic steps in the integration process (1). The
ﬁrst of these two reactions is 30-processing, which corre-
sponds to the speciﬁc cleavage of two nucleotides from the
30-ends of the linear viral DNA. The hydroxyl groups of
newly recessed 30-ends are then used in the second
reaction— strand transfer—for the covalent joining of
viral and cellular (or target) DNAs, resulting in full-site
integration. For both reactions, IN functions as a
multimer, most likely a dimer for 30-processing and a
tetramer (dimer of a dimer) for concerted integration
(2–7). Two other reactions occur in vitro, a disintegration
reaction that represents, in ﬁrst approximation, the
reversal of the half-site integration process (8) and a
speciﬁc internal cleavage occurring on a symmetrical
DNA site (9). All reactions require a metallic cofactor,
Mg
2+ or Mn
2+, and, except for disintegration (10,11),
all reactions require the full-length IN. There are several
experimental evidences to suggest that Mg
2+ is more
physiologically relevant as a cofactor, particularly
because Mg
2+-dependent catalysis exhibits weaker
non-speciﬁc endonucleolytic cleavage and the tolerance
of sequence variation at the ends of the viral DNA is
much greater in the presence of Mn
2+ than in the
presence of Mg
2+ (12–15).
The emergence of viral strains resistant against available
drugs and the dynamic nature of the HIV-1 genome
support a continued eﬀort towards the discovery and
characterization of novel targets and anti-viral drugs.
Due to its central role in the HIV-1 life cycle, IN repre-
sents a promising therapeutic target. In the past, in vitro
IN assays were extensively used to ﬁnd IN inhibitors (16).
Current inhibitors can be separated into two main classes,
depending on their mechanisms of action: (i) Compounds
that competitively prevent the DNA binding of IN to the
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the 30-processing reaction as they bind to the donor site
within the catalytic site—i.e. the ‘speciﬁc’ DNA-binding
site for the viral DNA -. This group is referred to as
‘integrase DNA-binding inhibitors’ (INBI) and includes
styrylquinoline compounds (17,18). (ii) The second class
includes compounds that cannot bind to the DNA-free
IN. They bind to the pre-formed IN–viral DNA
complex. These compounds preferentially inhibit strand
transfer over the 30-processing reaction [this family of
compounds is referred to as ‘integrase strand transfer
inhibitors’ (INSTI)], probably by displacing the viral
DNA end from the active site (7,19–21). It is not clear
whether this mechanism alone accounts for the inhibitory
properties of INSTIs or whether these compounds also
prevent the binding of the target DNA to the acceptor
site—i.e. the ‘non-speciﬁc’ DNA binding site. INSTI com-
pounds have generally good ex vivo activity against HIV
replication, probably due to their ability to inhibit
pre-assembled viral DNA/IN complexes. Raltegravir
which is currently used in clinical treatment of HIV-1
belongs to this class. For both anti-IN classes, resistance
mutations were identiﬁed (17,20,22,23). Diﬃculties in
deeply understanding their mechanisms of action are
closely related to the absence of structural data that
clearly delineate the donor and the acceptor DNA
binding sites in the active site. Although structural infor-
mation is now available regarding the IN–viral DNA
interaction, based on the recent crystal structure of the
full-length primate foamy virus (PFV-1) IN in complex
with its cognate processed viral DNA, the target DNA
binding mode and the precise location of the acceptor
site remains open to debate (7). Moreover, it is a diﬃcult
task to experimentally discriminate between the two DNA
binding sites and no signiﬁcant or only modest diﬀerence
can be evidenced in vitro (depending on the method used
for monitoring IN–DNA interactions) between the HIV-1
IN binding to the cognate viral DNA sequence and a
non-speciﬁc random sequence in terms of overall aﬃnity,
suggesting that the speciﬁc and the non-speciﬁc
DNA-binding modes display similar binding free
energies (5,24). The basis of DNA binding speciﬁcity
remains essentially unknown.
HIV-1 IN (288 amino acids) contains three functional
domains. The central domain or catalytic core domain
(IN
50–213 or CC) contains the catalytic triad (DDE) that
coordinates one or two metallic cofactors [probably a pair
coordinated by three carboxylate groups of the triad,
based on the X-ray structure of the PFV-1 IN (7)] and is
essential for enzymatic activity; this domain alone can
perform the disintegration reaction (10,11). This domain
is ﬂanked by the N-terminal (IN
1-49) and the C-terminal
(IN
214–288) domains. The C-terminal domain is involved in
IN–DNA contacts, together with the CC domain (25,26).
The N-terminal domain contains a conserved
non-conventional HHCC motif that binds zinc to ensure
proper domain folding and promotes IN multimerization
(27–29). It is worth noting that the integrity of the HHCC
motif is crucial in the stringent Mg
2+-context but appears
dispensable under the less stringent Mn
2+ condition (30),
suggesting, at least, an indirect role of the zinc-binding
domain in the establishment of speciﬁc and physiologi-
cally relevant IN–DNA complexes. In the structure of
the PFV-1 IN–viral DNA complex, the N-terminal
domain is also involved in the interaction with DNA (7).
In this article, we found that IN binds cooperatively to
the cognate viral DNA sequence only in the presence of
Mg
2+. The presence of Mn
2+ or, most importantly, the
use of non-speciﬁc random sequences, regardless of the
metallic cofactor, dramatically reduced the Hill coeﬃcient.
This ﬁnding suggests that the cooperative DNA-binding
mode of IN is strongly related to the formation of speciﬁc
IN–DNA contacts. To gain deeper insight into the
role of the zinc-binding domain in the cooperative/
multimerization process, in relationship with the establish-
ment of speciﬁc protein–DNA contacts, we studied the
eﬀect of DIBA-1 (2,20-dithiobisbenzamide-1) (Figure 1A)
on IN activity. This compound is a zinc ejector aﬀecting
many proteins containing zinc ﬁngers, including HIV-1
nucleocapsid or estrogen receptor (31–34). Here, we
found that DIBA-1 induced zinc ejection from the IN
N-terminal domain by covalently targeting the HHCC
motif. In the presence of Mg
2+, DIBA-1 did not aﬀect
signiﬁcantly the overall aﬃnity of IN for the DNA
substrate but dramatically reduced the Hill coeﬃcient.
Concomitantly, DIBA-1 strongly inhibited the catalytic
step, with IC50 values against the 30-processing reaction
of 11–15nM. Interestingly, we found a secondary
DIBA-1 binding site in the catalytic core (involving
residue Cys 56), suggesting a second mechanism of
action of DIBA-1, independent of zinc ejection. The prev-
alence of the two distinct mechanisms was dependent on
the cofactor context, with the second one accounting
for the weaker DIBA-1 inhibitory eﬀect under Mn
2+ con-
ditions (IC50=115–126nM). DIBA-1 behaves as a
non-competitive/catalytic inhibitor that did not disturb
the fractional saturation of DNA sites, regardless of the
mechanism considered.
Altogether, our results show that, although it is a diﬃ-
cult task to discriminate between the speciﬁc viral
sequence and a non-speciﬁc random sequence in terms
of overall aﬃnity, these sequences lead to distinct
DNA-binding properties in terms of cooperativity.
Moreover, our results highlight that the Mg
2+-dependent
catalytic activity of IN is strongly sensitive to the loss
of cooperative DNA binding. Such a cooperative
DNA-binding mode accounts for speciﬁc activity and
requires: (i) the cognate viral DNA sequence, (ii) Mg
2+
as a catalytic cofactor and (iii) zinc which can be consid-
ered as a positive allosteric eﬀector. Development of
non-competitive compounds acting on the N-terminal
domain may be of interest for anti-IN pharmacology.
MATERIALS AND METHODS
Oligonucleotides and DIBA-1
The oligonucleotides, U5A (50-GTG TGG AAA ATC
TCT AGC AGT), and its complementary strand, U5B
(50-ACT GCT AGA GAT TTT CCA CAC), mimicking
the HIV-1 DNA U5 extremity, were used for the
30-processing assay. For the DNA-binding assay, U5A
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U5A-30-F. The two random sequences used for DNA
binding were RAND1A (50-ACA TAA TCT AAA ATA
ATT GCC-30-F) and RAND2A (50-ACC TAT GCG CCG
CTA GAT TCC-30-F) and their complementary strands,
RAND1B and RAND2B, respectively. Disintegration
activity was measured using a dumbbell substrate
D( 5 0-TGC TAG TTC TAG CAG GCC CTT GGG
CCG GCG CTT GCG CC) as previously described (11).
One- and two-domain truncation constructs (N, C
and CC) were generated by PCR using the following
oligonucleotides: NPCR 50-CAT ATG CAT GGA
CAA GTA GAC TG; T7Term 50-TGC TAG TTA TTG
CTC AGC GG; CPCR 50-GGA TCC CTA TAA TTC
TTT AGT TTG TA; T7Prom 50-TAA TAC GAC TCA
CTA TAG G. All oligonucleotides were purchased from
Eurogentec (Liege, Belgium) and further puriﬁed by
electrophoresis on a 15% denaturing acrylamide/urea
gel. DIBA-1 was a generous gift from Sanoﬁ-aventis
(France).
Production and puriﬁcation of full-length and
truncated IN
All proteins (except IN
1–213) contain the C280S mutation
to avoid intermolecular disulﬁde bridges that promote
covalent multimers in the absence of reducing agents
(35). C56S, C65S and C56S-C65S mutations were
introduced (in the context of the C280S mutant) into a
pET-15b-IN plasmid encoding His-tagged HIV-1 IN
(18). Site-directed mutagenesis was done using
Stratagene’s Quickchange II Site-directed Mutagenesis
kit and veriﬁed by DNA sequencing. One- and
two-domain truncation constructs, IN
50–288 (or N),
IN
1–213 (or C) and IN
50–213 (or CC) were generated
from the full-length C280S IN by PCR. Primers
(NPCR and T7Term for N; T7Prom and CPCR
for C; NPCR and CPCR for CC) were designed to
generate DNA fragments containing an NdeI site at the
50-termini and a stop codon ﬂanked by a BamHI site at
the 30-termini. The resulting PCR fragments were ﬁrst
introduced in pGEM-T easy vector (Promega). The
sequences encoding for the diﬀerent truncated proteins
were then cloned into pET-15b plasmid after a double
NdeI–BamHI digestion. The diﬀerent His-tagged
proteins were overexpressed in Escherichia coli
BL21-codonplus (DE3+) (Stratagene) and puriﬁed as
previously described (18), with modiﬁcations. Brieﬂy, bac-
terial cultures were incubated at 37 C and protein expres-
sion was induced by IPTG (ﬁnal concentration, 0.25mM)
at OD600nm 0.7. The temperature was then lowered to
25 C and cultures were further incubated for 5h.
Puriﬁcation was performed using Ni-NTA beads
(Qiagen). The reducing agent (b-mercaptoethanol) was
removed during washing/elution steps and subsequent
dialysis. All puriﬁcation buﬀers were supplemented with
50mM ZnSO4 except for proteins used for quantiﬁcation
of Zn
2+ ejection by spectroscopy (see below), in order to
reduce the background signal due to free Zn
2+. Proteins
were aliquoted, rapidly frozen in liquid nitrogen, and
stored at  80 C. The full-length wild-type IN (used for
comparison with the C280S mutant in the ﬁrst section of
Results, Table 1) was puriﬁed as previously described (18)
without any modiﬁcation.
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Figure 1. DIBA-1 induces the ejection of zinc from IN. (A) Structure
of 2,20-dithiobisbenzamide-1 (DIBA-1) (MW, 614 Da). (B) Ejection of
zinc was measured by optical absorbance at 495nm using a sample
containing full-length IN (1mM) and PAR (10
 4M) in a Tris buﬀer
(20mM pH 7.0) containing 15% DMSO (v/v) in the absence of
reducing agent (black squares) or in the presence of 4mM
b-mercaptoethanol (white circles). The concentration of DIBA-1 for
complete zinc release—[DIBA-1]eq—was estimated graphically. This
value was determined as a function of the initial concentration of IN
(C). The slope of the straight line indicates that the zinc ejection coin-
cides with the reaction of two DIBA-1 molecules per IN protomer.
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Determination of IC50 values. For activity assays, 100
pmol of either U5A (30-processing substrate) or D (disin-
tegration substrate) were radiolabelled using T4
polynucleotide kinase and 50mCi of [g-
32P]ATP (3000Ci/
mmol). The T4 kinase was then heat inactivated. NaCl
was added to U5A and D (ﬁnal concentration, 100mM).
The complementary strand U5B was added to U5A. The
mixtures were incubated at 85 C for 5min and allowed
to anneal by slowly cooling to room temperature.
Unincorporated nucleotides were removed by ﬁltration
through a Sephadex G-25 column (GE Healthcare). The
30-processing or disintegration reactions were performed
using 1nM of either U5A/U5B or D DNA, respectively, in
a buﬀer containing 20mM Tris pH 7.0, 15% DMSO (v/v),
50mM NaCl, 10mM Mg
2+ or Mn
2+, full-length IN or
truncated proteins (concentrations are indicated in the
ﬁgure legends), and increasing amounts of DIBA-1. To
assess the inﬂuence of the order of addition of reagents
on the IC50 values, three diﬀerent protocols were tested:
(i) DIBA-1 was preincubated with the metallic cofactor
(for 15min at 25 C) before addition of IN and DNA
(protocol 1); (ii) DIBA-1 was preincubated with IN (for
15min at 25 C) before addition of the metallic cofactor
and DNA (protocol 2); (iii) IN was preincubated with the
metallic cofactor (for 15min at 25 C) before addition
of DIBA-1 and DNA (protocol 3). Reaction mixtures
were further incubated for 3h at 37 C, and then stopped
with 80ml of a buﬀer containing 6mM EDTA, 0.125mg/
ml glycogene, 400mM NaOAc, followed by a phenol–
chloroform extraction. DNA fragments were precipitated
with ethanol, dissolved in a loading buﬀer containing
20mM EDTA, 80% formamide, 0.05% bromophenol
blue, 0.05% xylene cyanol and subjected to electro-
phoresis on an 12% denaturing acrylamide/urea gel.
Gels were analyzed on a STORM 840
TM
PhosphorImager (Molecular Dynamics, Sunnyvale, CA,
USA) and quantiﬁed using Image QuanT
TM 4.1
software. The midpoint (IC50) of the inhibition curve
represents the drug concentration giving 50% inhibition.
DNA-binding assay and time-resolved
ﬂuorescence anisotropy
The interaction between IN and the 21-mer
double-stranded, ﬂuorescein-labeled oligonucleotide
(U5A/U5B, RAND1A/RAND1B or RAND2A/
RAND2B) was detected by steady-state ﬂuorescence
anisotropy using a Beacon 2000 instrument (PanVera,
Madison, WI, USA) (3,18,36). The double-stranded
DNA was obtained by mixing equimolar amounts of com-
plementary strands (B and A-30-F) in a 20mM Tris–HCl
buﬀer (pH 7.0) containing 100mM NaCl. The mixture
was heated to 85 C for 5min and allowed to anneal by
slowly cooling to room temperature. To determine the
apparent Kd-value (Kd,app), ﬂuorescein-labeled DNA
(1nM) was incubated with increasing concentrations of
IN (full-length or truncated proteins) in a 20mM Tris
buﬀer (pH 7.0) containing 15% DMSO (v/v), 50mM
NaCl and 10mM MnCl2 or MgCl2 for 20min at 25 C,
and the steady-state anisotropy (r) was then recorded. In
the presence of DIBA-1, titration experiments were per-
formed with a constant DIBA-1:IN ratio (from 1:1 to 3:1).
The fractional saturation Y was calculated as (r rfree)/
(rbound rfree), where rbound and rfree represent the bound
and free DNA anisotropy, respectively. The Hill number,
n˜, was calculated by directly ﬁtting the titration curve
using the Hill function in Origin 6.0 software. Kd,app or
IN50 represents the concentration of IN required to titrate
the DNA to half saturation. Hydrodynamic characteriza-
tion of the IN–DNA complexes (using ﬂuorescein-labeled
DNA U5A/U5B or RAND1A/RAND1B), via the deter-
mination of the rotational correlation times, was per-
formed by time-resolved ﬂuorescence anisotropy as
previously described (3), i.e. under optimal condition for
30-processing activity when using the viral sequence:
[DNA]=5nM and [IN]=200nM (in the same buﬀer
used for DNA-binding assay).
Determination of zinc release by DIBA-1
The ejection of zinc from IN was quantiﬁed using the
chromophoric chelator 4-(2-pyridylazo)resorcinol (PAR)
(Sigma). Zn
2+ release by DIBA-1 was monitored by
absorbance using a Uvikon 941 (Kontron) spectro-
photometer as the formation of the Zn
2+-(PAR)2
complex enhances absorbance at 495nm. All experiments
were conducted in a Tris buﬀer (20mM, pH 7.0) contain-
ing 15% DMSO (v/v) to improve the solubility of
DIBA-1. The molar extinction coeﬃcient of the Zn
2+-
(PAR)2 complex was measured in the presence of
DMSO (15%) using zinc solutions of known concentra-
tions (from 1 to 6mM). A molar extinction coeﬃcient of
6.1 10
4M
 1cm
 1 was found in 15% DMSO, a value
slightly lower than the one previously found in water
(6.6 10
4M
 1cm
 1) (37).
Characterization of DIBA-1 modiﬁed IN
by mass spectrometry
The covalent modiﬁcation of IN by DIBA-1 was
evaluated using in-gel tryptic digestion and SELDI mass
spectrometry analysis. To enhance the enzymatic diges-
tion, we used the ProteaseMAX
TM Surfactant, Trypsin
Enhancer (Promega, France) as described by the manu-
facturer. IN (20mM), preincubated or not with DIBA-1
(40mM) in 20mM HEPES (pH 6.9), DMSO 15%
(v/v), NaCl 400mM, was subjected to SDS–PAGE
electrophoresis (without DTT). After Coomassie
staining, the gel slides were destained twice in 50mM
Table 1. Hill coeﬃcients characterizing the binding of HIV-1
full-length IN to diﬀerent DNA sequences
a
Metallic
cofactor
b
Hill coeﬃcient
U5A/
U5B
RAND1A/
RAND1B
RAND2A/
RAND2B
Mg
2+ 1.97±0.10 1.17±0.06 1.20±0.07
Mn
2+ 1.29±0.09 0.90±0.06 0.92±0.10
aSee ‘Materials and Methods’ section for details.
b10mM.
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50mM NH4CO3, 50% acetonitrile (v/v) (200ml) for
5min and, ﬁnally, dried in a Speed Vac. No
DIBA-1-mediated inter-molecular crosslink was evidenced
by gel-electrophoresis. The gel slides were then rehydrated
in a NH4CO3 (50mM) solution containing 12ng/ml
trypsin and 0.025% ProteaseMAX
TM Surfactant, for
10min, and further incubated overnight (protocol A:
PA) or 2h (protocol B: PB) at 37 C. The resulting
peptides were recovered either by addition of a 10ml
solution containing 0.01% ProteaseMAX
TM Surfactant
in NANOpure water (PA) or by concentration/puriﬁca-
tion using Zip Tip C18 (Millipore) [Elution with a 80%
acetonitrile (v/v), 0.1% TFA solution] (PB), and spotted
onto a SEND-ID protein array according to Ciphergen’s
protocol. The mass spectra were obtained by reading the
protein chip using a SELDI mass spectrometer. The
resulting spectra were compared with the in silico proﬁle
obtained with GPMAW software (Lighthouse Data).
RESULTS
We have previously shown that IN binding to an
oligonucleotide mimicking the HIV-1 U5 DNA extremity
was cooperative in the presence of Mg
2+ and
characterized by a Hill coeﬃcient of 2 (18), consistent
with both time-resolved ﬂuorescence anisotropy (3,5)
and cross-linking (2) experiments showing that a dimer
of IN corresponds to the catalytically active form for the
30-processing reaction. This result supports a model in
which the dimer originates from the cooperative
assembly of two protomeric units on the viral DNA end
(3,5,38). In the present study, we addressed the question of
whether the above-mentioned cooperative property was
dependent or not on the DNA sequence context (viral
versus random) or the nature of the metallic cofactor
(Mg
2+ versus Mn
2+).
The cooperative binding of IN to DNA is modulated
by the cofactor and the DNA sequence
We used steady-state ﬂuorescence anisotropy for monitor-
ing IN–DNA interaction as previously described (3,18,36).
IN binding to the viral DNA sequence (U5A/U5B) was
characterized by a Hill coeﬃcient (n˜) of 1.97 in the
presence of Mg
2+ (Table 1), indicating cooperativity, in
accordance with our previous study (18). It was previously
shown that the 30-processing activity is much more sensi-
tive to the viral DNA sequence in the Mg
2+ context than
the Mn
2+ context, suggesting that speciﬁc contacts
between IN and the viral DNA extremity are more
favored in the presence of Mg
2+ (12,13). To gain insight
into the cooperativity–speciﬁcity relationship, we ﬁrst
tested whether the cooperative property was dependent
or not on the nature of the metallic cofactor. Using the
cognate viral DNA sequence (U5A/U5B), we found that
Mg
2+- and Mn
2+-dependent DNA-binding display diﬀer-
ent Hill coeﬃcients, with a DNA-binding process that is
more cooperative in the presence of Mg
2+ (n˜=1.97 and
1.29 for Mg
2+ and Mn
2+, respectively; Table 1). It is
important to note that IN does not strictly require a
divalent cation for DNA binding (3,25). It was then
possible to assess the cooperative behaviour of IN in the
absence of metallic cofactor. The corresponding n˜ value
(n˜=1.34) (see also Table 4) was found to be similar to the
value obtained with Mn
2+ (n˜=1.29). The concentration
of Mg
2+ compatible with cooperativity was found in the
5–15mM concentration range (the IN–DNA interaction is
signiﬁcantly reduced above 15mM Mg
2+).
We next assessed whether IN binding to non-speciﬁc
random DNA sequences was cooperative or not. Two
random sequences were tested (RAND1A/RAND1B or
RAND2A/RAND2B). In the presence of Mg
2+, the Hill
coeﬃcient was signiﬁcantly reduced when using these
DNA sequences (n˜ 1.2; Table 1). Clearly, the coopera-
tive DNA-binding mode (n˜=1.97) requires both the
cognate viral sequence and Mg
2+ as a cofactor: Mn
2+-
dependent DNA binding on the cognate sequence or
Mg
2+-dependent DNA binding on the random DNA
sequences signiﬁcantly decreased the Hill number.
Moreover, cooperativity was totally abolished with
Mn
2+ and a random DNA sequence (n˜ 0.9–0.92;
Table 1). Similar results were obtained with the
wild-type protein and the C280S mutant (used throughout
the rest of this article; see below). Importantly, the mod-
ulation of the Hill number was not correlated to a
change in the degree of IN oligomerization. In fact, the
long rotational correlation times (y) [as monitored by
time-resolved ﬂuorescence anisotropy (3)], characterizing
the following complexes: IN-Mg
2+-viral sequence,
IN-Mn
2+-viral sequence, IN-Mg
2+-random sequence,
were not signiﬁcantly diﬀerent (Table 2): All y values
(in the 39–44ns range at 25 C) were compatible with a
dimeric form of IN bound to DNA, in agreement with
our previous study of the IN-Mg
2+–viral DNA complex
[y=37.8ns in (3)].
Taken together, our results show that the formation of
speciﬁc IN–DNA complexes is concomitant to the
presence of a cooperative DNA-binding mode. Of partic-
ular interest is the observation that cooperativity measure-
ments allow to distinguish between speciﬁc and
non-speciﬁc DNA-binding modes. Nevertheless, we
observed only a slight diﬀerence in the apparent Kd,app
values between Mg
2+ and Mn
2+ (Kd,app=65 and
51nM, respectively; Table 3, ﬁrst line) and we did not
observe any signiﬁcant diﬀerence in the Kd,app values
between the diﬀerent sequences for a given metallic
cofactor (data not shown). Moreover, the Kd,app value in
the absence of divalent cation was found to be 40nM
(Table 3), conﬁrming that the presence of either metallic
cofactor is not crucial for the overall DNA-binding
process. Therefore, the nature of the metallic cofactor or
the DNA sequence has no signiﬁcant inﬂuence on the
overall IN–DNA aﬃnity, suggesting that non-speciﬁc
contacts constitute the main driving force for the
complex stability, while speciﬁc contacts, probably
mediated by a cooperative mechanism of assembly, are
essential for ﬁne positioning of IN with respect to the
cleavage site and subsequent catalysis. It has been
reported that Mg
2+/Mn
2+ stimulate the preferential rec-
ognition of the cognate sequence by HIV-1 IN (as shown
by the decrease in the Kd-value measured by SPR assay)
3696 Nucleic Acids Research, 2010,Vol.38, No. 11(24). One possible reason to explain this apparent contra-
diction with our data is that the study by Yi and collab-
orators was carried out at high ionic strength (300mM),
while our experiments were conducted under low ionic
strength conditions (50mM). Indeed, we have previously
shown that ionic strength selectively disrupts non-speciﬁc
IN–IN interactions, using PFV-1 IN, accounting for the
observed diﬀerential DNA binding between viral and
random sequences at 150mM NaCl, while no diﬀerence
was evidenced at 50mM NaCl (5). Such a diﬀerential
DNA binding was not observed for HIV-1 IN, even at
150mM NaCl (5). This is explained by the lower propen-
sity of PFV-1 IN to mediate non-speciﬁc IN–IN interac-
tions, and probably, a higher ionic strength (i.e. 300mM)
is required in the case of HIV-1 IN to distinguish between
speciﬁc and non-speciﬁc complexes in terms of aﬃnity.
However, it is important to note that ﬂuorescence
anisotropy experiments did not show any binding of
HIV-1 IN to DNA at 300mM NaCl (up to 3mM IN)
(data not shown). Further investigation is required to
understand the exact reason of this discrepancy between
SPR and ﬂuorescence anisotropy results.
Zinc ejection by DIBA-1 inﬂuences the cooperative
binding of IN to the DNA substrate but does not
prevent IN–DNA interactions
Taking into account that zinc promotes the Mg
2+-depen-
dent activity of IN and has no or a modest inﬂuence on the
Mn
2+-dependent activity (28,29), we next assessed
whether zinc ejection may inﬂuence the cooperative
DNA-binding properties of IN, using DIBA-1 (Figure
1A), a zinc ejector compound that can react with zinc
ﬁngers (33). In the following sections, we tested the eﬀect
of DIBA-1 in the context of the C280S mutation, taking
into consideration that (i) puriﬁcation and assay buﬀers
were non-reducing (without DTT and b-mercaptoethanol)
to avoid DIBA-1 reduction, (ii) the C280 residue was
described to be responsible for the formation of covalent
multimers under non-reducing conditions (35), (iii) the
C280S mutation does not aﬀect viral replication or in
vitro IN activity (35). We ﬁrst tested whether DIBA-1
ejected zinc from IN by spectroscopy using the
chomophoric chelator 4-(2-pyridylazo)resorcinol (PAR).
Figure 1B clearly shows that DIBA-1 triggered zinc
release from IN (conﬁrmed below by mass spectroscopy
analysis demonstrating that DIBA-1 targets the HHCC
motif). This eﬀect was counteracted by a reducing
agent such as b-mercaptoethanol (Figure 1B). According
to the molar extinction coeﬃcient of Zn
2+–(PAR)2
Table 3. Kd,app values for DNA-binding of the full-length and truncated IN in the presence or absence of DIBA-1
a
Kd,app,n M
IN 10mM Mg
2+ 10mM Mn
2+ No divalent cation
DIBA  DIBA+
b DIBA  DIBA+
b DIBA  DIBA+
b
Full-length 65±7 65±9 51±7 53±5 40±15 48±11
N 45±7 45±6 28±3 29±6 ND ND
C 531±188 652±214 60±4 64±8 ND ND
CC 233±98 279±34 53±13 61±10 ND ND
aThe DNA sequence corresponds to the HIV-1 U5 extremity (U5A/U5B) (see ‘Materials and Methods’ section).
bCorresponding to a DIBA-1:IN ratio of 3:1.
ND, not determined.
Table 4. Hill coeﬃcients for DNA-binding of the full-length and truncated IN in the presence or absence of DIBA-1
a
Hill coeﬃcient
IN 10mM Mg
2+ 10mM Mn
2+ No divalent cation
DIBA  DIBA+
b DIBA  DIBA+
b DIBA  DIBA+
b
Full-length 1.97±0.10 1.47±0.02 1.29±0.09 1.20±0.10 1.34±0.08 1.37±0.09
N 1.45±0.12 1.41±0.10 1.20±0.06 1.30±0.13 ND ND
C 1.90±0.10 1.43±0.12 1.24±0.07 1.21±0.11 ND ND
CC 1.38±0.09 1.32±0.06 1.26±0.13 1.20±0.05 ND ND
aThe DNA sequence corresponds to the HIV-1 U5 extremity (U5A/U5B) (see ‘Materials and Methods’ section).
bCorresponding to a DIBA-1:IN ratio of 3:1.
Table 2. Long correlation times characterizing diﬀerent IN–DNA
complexes
a
DNA sequence U5A/U5B U5A/U5B RAND1A/
RAND1B
Metallic cofactor
b Mg
2+ Mn
2+ Mg
2+
Long correlation
time
39.1±4.5ns 43.9±5.1ns 41.4±4.8ns
aObtained at 25 C with [IN]=200nM and [DNA]=5nM (see
‘Materials and Methods’ section).
b10mM.
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4M
 1cm
 1) and the IN
concentration (1mM), the absorbance value at the plateau
(0.055) indicates a zinc content of 0.9 eq Zn
2+ per IN
monomer, in agreement with the expected value for a
protein encompassing one zinc-ﬁnger domain. Moreover,
we found that the reaction of two DIBA-1 molecules per
IN monomer coincides with zinc release (Figure 1C). This
result will be further discussed (see ‘Discussion’ section).
The DIBA-1-mediated zinc ejection from IN prompted
us to study the inﬂuence of DIBA-1 on the catalytic
activity of IN. DIBA-1 strongly inhibited the 30-processing
and disintegration catalyzed by the full-length IN with
IC50 values of 11–15 nM for both reactions in the
presence of Mg
2+ (Figure 2A–D). The IC50 values were
signiﬁcantly higher in the presence of Mn
2+ (115–126
nM). All these reactions were carried out in the absence
of reducing agent to prevent DIBA-1 reduction. Indeed,
adding DTT or b-mercaptoethanol to the reaction mixture
blocked the DIBA-1 inhibitory eﬀect (Figure 2E).
Recently, it has been reported that complexation reactions
between bis(2-bromophenyl)disulﬁde and transition metal
ions, including manganese, may occur (39). To address the
question of the possible complexation between DIBA-1
and Mn
2+—which could explain the higher IC50 values
obtained in the presence of Mn
2+ compared to Mg
2+—
we tested the inﬂuence of the order of addition of the
reagents on the IC50 value. Three diﬀerent preincubation
protocols were tested (see ‘Materials and Methods’
section). No signiﬁcant inﬂuence of the order of addition
of the reagents on the IC50 values was observed, i.e. the
three protocols lead to similar IC50 values for a given
metallic cofactor. In particular, for Mn
2+, the comparison
between protocols 1 (when DIBA-1 is preincubated with
Mn
2+ before addition of IN and DNA) and 2 (when
DIBA-1 is preincubated with IN before addition of
Mn
2+ and DNA) suggests that, under our experimental
conditions, Mn
2+ does not interact or only weakly inter-
acts with DIBA-1, to an extent that does not signiﬁcantly
aﬀect the concentration of free DIBA-1 molecules, avail-
able to react with IN. Moreover, the similar IC50 values
obtained between protocols 2 and 3 (when IN is
preincubated with the metallic cofactor before addition
of DIBA-1 and DNA), indicates that the binding of
either Mn
2+ or Mg
2+ to IN is not a prerequisite for the
reaction of DIBA-1 with IN. Altogether, these data
suggest that the inﬂuence of the cofactor context on the
IN inhibition by DIBA-1, is not explained by a substantial
decrease in the eﬀective concentration of the inhibitor in
the presence of Mn
2+.
We next performed DNA-binding assays to test whether
DIBA-1 could inhibit IN activity via inhibiting the
IN–DNA interaction (i.e. DIBA-1 behaves as a competi-
tive inhibitor), as found for the compounds of the
styrylquinoline family (INBI) (18), or acts at the catalytic
step (post-DNA-binding step event). Increasing concen-
trations of the full-length IN were added to a
ﬂuorescein-labeled DNA that mimics the HIV-1 U5
DNA extremity and ﬂuorescence anisotropy was
measured in the absence (Figure 3, top, black squares)
or presence (white squares) of DIBA-1 at a constant
DIBA-1:IN ratio (2:1). Results clearly show that
DIBA-1 did not prevent the DNA binding of IN. The
corresponding 30-processing activities are also reported
for each condition and conﬁrm that DIBA-1 did eﬃciently
inhibit 30-processing activity under conditions that did not
signiﬁcantly aﬀect the amount of IN-DNA complexes
(Figure 3, top, compare black and white circles). The
apparent Kd-values for the full-length protein were
similar, regardless of the metallic cofactor used, and inde-
pendent of the presence of DIBA-1 (Table 3, ﬁrst line),
conﬁrming that DIBA-1 allows IN to bind to its DNA
substrate but inactivates the formed complexes. This
result is in sharp contrast to the one previously observed
with styrylquinoline compounds (such as FZ55, Khd161
and FZ41) for which the inhibition of the 30-processing
activity was found to closely parallel the inhibition of
the formation of IN–DNA complexes as monitored by
ﬂuorescence anisotropy (3,18). We then tested and
compared FZ41 and DIBA-1 for their inhibitory eﬀects
on the DNA binding step (as monitored by ﬂuorescence
anisotropy), under the same experimental conditions, i.e.
by using a Tris:DMSO mixture (85:15) (v/v) containing
constant concentrations of IN and DNA, and increasing
concentrations of drugs (Figure 3, bottom). FZ41 was
found to inhibit the binding of IN to DNA with an IC50
value of 0.75mM (black triangles), in agreement with the
IC50 value characterizing the 30-processing inhibition
(3,40). This result conﬁrms that the inhibition of the
30-processing activity by styrylquinoline compounds is
fully explained by the prevention of IN–DNA recognition.
In contrast, no inhibition of the IN-DNA interaction was
evidenced with DIBA-1 using the same DNA-binding
assay (white squares).
Remarkably, even though DIBA-1 had no measurable
eﬀect on the overall aﬃnity, it signiﬁcantly reduced the
Hill coeﬃcient from 2 to 1.47 (Figure 4 and Table 4),
suggesting that DIBA-1 interferes with the cooperative
binding of IN to DNA. As mentioned above, such a coop-
erative binding was not observed in the presence of Mn
2+
or in the absence of divalent cation (n˜=1.29 and 1.34,
respectively), and DIBA-1 did not further change these n ˜
values (n˜=1.20 and 1.37, respectively) (Table 4). This
result suggests that the DIBA-1 eﬀect on the cooperative
DNA-binding mode is strongly related to the diﬀerential
inhibition by DIBA-1 of Mn
2+- and Mg
2+-dependent IN
activities, as above-mentioned [a better inhibitory eﬀect,
 10-fold, was systematically found in the Mg
2+ context
compared to Mn
2+ (Figure 2)]. Altogether, our results
show that the N-terminal domain and its HHCC motif
do not play a direct role in terms of aﬃnity/stability of
the IN–DNA complex, but, most likely, account for the
observed Mg
2+-dependent cooperative behavior of IN via
protein–protein interactions. We also compared the
DNA-binding properties of the full-length IN with
truncated proteins: IN
50–288 (N), IN
1-213 (C) and
IN
50–213 (CC). All proteins were able to bind to the
DNA substrate (Table 3), although truncated proteins
are inactive for 30-processing. The C-terminal domain
plays a key role for the aﬃnity of the IN-DNA complex
but only in the Mg
2+ context, whereas the Kd,app values in
Mn
2+ were all similar (Table 3, lines 3 and 4). This ﬁnding
agrees with previous works showing that the C-terminal
3698 Nucleic Acids Research, 2010,Vol.38, No. 11P, 19-mer
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Figure 2. Inhibition of 30-processing and disintegration by DIBA-1. 30-Processing (A) or disintegration (B) reactions were performed in the presence
of DIBA-1 with either 10mM Mg
2+ (left) or 10mM Mn
2+ (right), full-length IN (50nM) and DNA substrate (1nM) (except lane 1: no integrase).
DIBA-1 concentration was 0 (lane 12), 1.9nM (lane 11), 3.8nM (lane 10), 7.7nM (lane 9), 15.4nM (lane 8), 30.8nM (lane 7), 61.5nM (lane 6), 123
nM (lane 5), 370nM (lane 4), 1111nM (lane 3) or 3333nM (lane 2). S, DNA substrate. P, DNA product. Relative activities of 30-processing (C)o r
disintegration (D) (with either Mg
2+, black squares; or Mn
2+, white circles, as a metallic cofactor) were plotted against the DIBA-1 concentration.
In the presence of Mg
2+, the calculated IC50 values were 13 and 11nM for 30-processing and disintegration reactions, respectively. The corresponding
values in the presence of Mn
2+ were 118 and 123nM, respectively. Similar results were obtained regardless of the preincubation protocol used (1, 2
or 3; see ‘Materials and Methods’ section). (E) Eﬀect of reducing agents on the inhibitory activity of DIBA-1. 30-Processing reaction was performed
using full-length IN (100nM), DNA substrate (1nM) and Mg
2+ (10mM) as a cofactor (lanes 2–9). IN was preincubated (for 10min at room
temperature) alone (lane 2), with DIBA-1 (lane 3) or DTT (lane 4) or b-mercaptoethanol (lane 5), before addition of Mg
2+ and DNA; lanes 6 and 8,
IN/Mg
2+ was preincubated with DIBA-1 for 10min at room temperature before adding the reducing agent and DNA (lane 6, DTT; lane 8,
b-mercaptoethanol); lanes 7 and 9, IN/Mg
2+ was preincubated with the reducing agent (lane 7, DTT; lane 9, b-mercaptoethanol) for 10min at
room temperature before adding DIBA-1 and DNA. Concentrations of DTT and b-mercaptoethanol were 4mM. Concentration of DIBA-1 was 200
nM. Lane 1, DNA alone.
Nucleic Acids Research, 2010,Vol.38, No. 11 3699domain is critical for overall IN–DNA complex stability.
However, the diﬀerential inﬂuence of the divalent cations
on the aﬃnity also suggests that this domain could be
involved in speciﬁc interactions with DNA, assuming
that Mg
2+-dependent catalysis is more sequence-speciﬁc
than Mn
2+-dependent catalysis (12,13). In contrast, the
role of the N-terminal domain in the complex stability
appears to be much less important as its deletion does
not decrease the aﬃnity, consistent with the absence of
any signiﬁcant eﬀect of zinc ejection on the Kd,app
values. There is rather a slight increase in the aﬃnity
(decrease in the Kd,app value) upon deletion of the
N-terminal domain (Table 3; compare the full-length to
the N protein—lines 1 and 2—and compare the C to
the CC protein—lines 3 and 4).
Regarding the Hill coeﬃcients characterizing truncated
proteins in the presence of Mg
2+ (Table 4), only C dis-
played high cooperativity (n˜=1.9) as the full-length IN.
In contrast, N and CC proteins, lacking the N-terminal
domain, were characterized by lower n˜ values (1.45 and
1.38, respectively). Importantly, the Hill coeﬃcient of the
C protein signiﬁcantly decreased in the presence of
DIBA-1 (n˜=1.43), in a similar manner to that of the
full-length IN, whereas DIBA-1 did not further decrease
the n ˜ values of the N and CC proteins (1.41 and 1.32,
respectively). Moreover, as found with the full-length IN,
the Hill coeﬃcients of all truncated proteins were lower in
the presence of Mn
2+ (1.20–1.26) and were not inﬂuenced
by the presence of DIBA-1.
In conclusion, DIBA-1 did not prevent the formation of
IN–DNA complexes, but, in the Mg
2+ context,
signiﬁcantly changed the Hill coeﬃcient, suggesting that
the nature of the IN–IN interaction onto the DNA
substrate or the oligomeric status of the IN–DNA
complex is modulated by DIBA-1. Altogether, our
results show that the N-terminal domain mainly
mediates the cooperative binding of Mg
2+-bound IN to
the cognate DNA sequence. However, the Mn
2+-depen-
dent 30-processing and disintegration activities performed
by full-length IN remained sensitive to DIBA-1, albeit less
sensitive than Mg
2+-dependent activities, suggesting that
the loss of cooperativity does not fully explain the IN
inhibition, especially in the Mn
2+ context. To better
understand the IN domains involved in the DIBA-1
response, we next tested the DIBA-1 eﬀect on truncated
INs such as double-domain proteins, N and C, as well
as the single-domain catalytic core, CC. We used the dis-
integration assay to test activity in the presence of Mn
2+,
which is required for disintegration activity of truncated
proteins, as these proteins cannot catalyze the
30-processing or Mg
2+-dependent disintegration (11). All
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Figure 3. DIBA-1 does not prevent formation of IN–DNA complexes.
Top, increasing concentrations of IN were incubated with DNA
substrate (1nM) in a Tris buﬀer (20mM, pH 7.0) containing 15%
DMSO (v/v), NaCl 50mM and 10mM Mg
2+. Left axis, the DNA
binding step was recorded by ﬂuorescence anisotropy as described in
‘Materials and Methods’ section. Black squares, no DIBA-1. White
squares, [DIBA-1]:[IN]=2: 1. Right axis, 30-processing activity for
IN/DNA mixtures (measured as described in ‘Materials and Methods’
section with preincubation conditions corresponding to protocol 3).
Black circles, no DIBA-1. White circles, [DIBA-1]:[IN]=2: 1.
Similar qualitative proﬁles were obtained using Mn
2+ as a cofactor,
but with a less potent inhibition of the 30-processing reaction, according
to Figure 2 (data not shown). Bottom: IN (120nM) was incubated with
DNA substrate (1nM) in a Tris buﬀer (20mM, pH 7.0) containing
15% DMSO (v/v), NaCl 50mM, 10mM Mg
2+, and increasing concen-
trations of either FZ41 (black triangles) or DIBA-1 (white squares).
The binding of IN to DNA was monitored by ﬂuorescence anisotropy.
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Figure 4. Hill coeﬃcient as a function of the DIBA-1:IN ratio.
DNA-binding isotherms were recorded as described in the legend of
Figure 3.
3700 Nucleic Acids Research, 2010,Vol.38, No. 11truncated proteins, including CC, remained inhibited by
DIBA-1, but with higher IC50 values than the full-length
IN (Figure 5). Therefore, the inhibition does not strictly
require the zinc-ﬁnger, as DIBA-1 can still inhibit
truncated mutants lacking the N-terminal domain. This
result highlights another eﬀect of DIBA-1, i.e. DIBA-1
can directly aﬀect the catalytic core, independent of zinc
ejection.
Mass spectrometry analysis of IN–DIBA-1 complexes: the
DIBA-1 compound covalently targets both the N-terminal
HHCC motif and the catalytic core
SELDI-MS analysis of the full-length IN was performed
after a trypsin digestion of IN with or without DIBA-1. A
protein coverage of  92% was obtained, regardless of the
protocol used (PA or PB; see ‘Materials and Methods’
section) (Figure 6A). The molecular mass of two
peptides was modulated by DIBA-1 (using PA or PB)
(Figure 6B). The ﬁrst one (pos. 35/42) contained the
Cys 40 residue, conﬁrming that DIBA-1 targets at
least one cysteine residue in the N-terminal HHCC
motif. The second peptide (pos. 47/71) contained both
Cys 56 and Cys 65, conﬁrming that the catalytic core is
also targeted by DIBA-1. Additionally, our results show
that the Cys 130 residue is not targeted by DIBA-1 as no
inﬂuence of DIBA-1 was evidenced on peptides 112/136
and 128/136 (with PA or PB) (Figure 6C). Using PA,
no adduct species were evidenced, probably for
hydrophobicity reasons, even though the peptides 35/42
(MW, 864 Da) and 47/71 [MW, 2711 Da; MW(+16),
2727 Da] were reproducibly absent in samples treated
with DIBA-1. In contrast, an adduct product was
observed using PB (MW, 3034 Da), corresponding to a
covalent complex between the oxidized peptide 47/71
(MW(+16), 2727 Da) and a DIBA-1 monomer (MW,
307 Da) (no adduct product related to the 35/42 peptide
was detected, even using PB). This product corresponds
however to a minor species (data not shown).
Importantly, a dominant adduct product (MW, 3795
Da; MW(+16), 3811 Da) was concomitantly observed
only with samples treated with DIBA-1 (using PB)
(Figure 6D): This product originates from a miscleavage
leading to a peptide [pos. 43/71; MW, 3182 Da;
MW(+16), 3198 Da] covalently modiﬁed by DIBA-1.
The MW diﬀerence (+614 Da) suggests that two of the
three cysteine residues contained in this peptide (C43, C56,
C65) are involved in a covalent complex with a DIBA-1
monomer (+307 Da per cysteine) according to the general
mechanism proposed by Loo et al. (41) (see also Figure
6E). This result also suggests that the tryptic proteolysis
occurring at K46 is altered in DIBA-1-treated samples (no
unmodiﬁed 43/71 peptide was found in untreated
samples). Altogether, our results indicate that DIBA-1
covalently targets three cysteine residues within IN, (i)
Cys 40 and Cys 43 in the HHCC motif and, (ii) Cys 56
or Cys 65 in the central domain. The results were similar
regardless of the divalent cation used (Mg
2+ or Mn
2+).
Thus, DIBA-1 targets both the zinc-ﬁnger motif in the
N-terminal domain and the active site in the CC domain
and the nature of the metallic cofactor does not inﬂuence
the binding proﬁle of DIBA-1.
To discriminate between Cys 56 and Cys 65, we per-
formed site-directed mutagenesis. The C56S, C65S and
C56S-C65S mutants were generated (in the context of
the C280S mutation) and tested for DIBA-1 sensitivity.
The three mutants display similar 30-processing activity
as the native protein (C280S only) (data not shown).
DIBA-1 inhibited the C65S mutant in Mn
2+ with a
similar IC50 as the native protein (Table 5). In contrast,
DIBA-1 inhibition was much less potent with C56S and
C56S/C65S mutants, indicating the importance of the Cys
56 residue in DIBA-1 binding and, then, in mediating the
inhibition of IN activity. Accordingly, it was shown by
others that modifying Cys 56 by N-ethylmaleimide simi-
larly inactivates IN (42). This ﬁnding was conﬁrmed by
the MS analysis of the C56S mutant. In contrast to the
result obtained with the C56 protein, no inﬂuence of
DIBA-1 on the molecular mass of the 47/71 peptide was
evidenced with the S56 protein (only the molecular mass
of the 35/42 peptide was modulated by DIBA-1) (data not
shown). Moreover, no adduct species equivalent to either
the 3034 Da (MWeq, 3019 Da for S56) or the 3795(+16)
Da product [MWeq, 3780(+16) Da for S56], previously
identiﬁed with the C56 protein (using PB), were evidenced
with S56 under similar experimental conditions. Similar
MS results were obtained, regardless of the cofactor
used. However, regarding the inhibition of 30-processing,
results were diﬀerent in Mg
2+ compared to Mn
2+:
DIBA-1 was equally potent in all mutants (only a
modest increase of the IC50 value was observed with the
C56S or the C56S–C65S mutant), and more potent than in
Mn
2+ (Table 5). This suggests that the consequence of
DIBA-1 binding to the N-terminal domain (i.e. zinc
ejection) dominates in Mg
2+ and that this mechanism
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Figure 5. Eﬀect of DIBA-1 on the full-length IN and truncated
mutants. Disintegration reactions were performed in the presence of
10mM Mn
2+ as described in ‘Materials and Methods’ section (the
preincubation step was carried out according to protocol 3). Relative
activities of disintegration were plotted against the DIBA-1 concentra-
tion (black circles, full-length IN; white circles, N; white squares, C;
black squares, CC). The calculated IC50 values were 95, 234, 1135 and
191nM for full-length, N, C and CC proteins, respectively. Protein
and DNA substrate concentrations were 50nM and 1nM, respectively.
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Figure 6. SELDI analysis of in-gel proteolysis of DIBA-1 modiﬁed IN. The SELDI analysis of trypsin digestion of HIV-1 IN, treated or not with
DIBA-1, was carried out as described in ‘Materials and Methods’ section. (A) Primary sequence of HIV-1 IN. The tryptic peptides obtained after
proteolysis were analyzed using a SEND-ID protein chip. The protein coverage was 92% (corresponding sequences are underlined). (B) Sequences of
the recovered peptides for IN sample not treated with DIBA-1. The underlined sequences correspond to shifted m/z peaks when IN was initially
treated with DIBA-1 before in-gel proteolysis.
a ‘+16’ or ‘+16,+32’ means that the same peptide can be represented by two or three peaks,
respectively: The ﬁrst one corresponds to the non-oxidized form. The second and the third peak correspond to the presence of one or two
oxidized residues (methionine or tryptophan) resulting in a mass shift of +16 or +32 Da, respectively. (C and D) MS spectra magniﬁed in two
regions of interest (top, untreated sample; bottom, DIBA-1-treated sample), showing that: (C) DIBA-1 had no eﬀect on the 128/136 peptide (MW,
1005 Da) containing the C130 residue [a similar result was obtained with the 112/136 peptide (MW, 2696 Da) (data not shown)]; (D) A new peak
[MW, 3795 (+16) Da] was identiﬁed in the presence of DIBA-1, compatible with the formation of a covalent complex between the 43/71 peptide
[MW, 3182.63 (+16) Da] and two DIBA-1 monomers (MW, 2 307 Da) (see text for details). (E) Models for the reaction pathways involving
DIBA-1 and: (i) the IN HHCC motif in the N-terminal domain (top), (ii) the Cys 56 residue of the catalytic core domain (bottom).
3702 Nucleic Acids Research, 2010,Vol.38, No. 11fully accounts for the inhibition of the Mg
2+-dependent
activity of IN. In contrast, zinc ejection and its conse-
quence on the cooperative DNA-binding properties of
IN are neutral in terms of catalysis in the Mn
2+ context
according to (30), and thus, catalytic performance
becomes more sensitive to perturbation of the active site
in Mn
2+. The Mn
2+-dependent activity is then primarily
aﬀected by the direct reaction of DIBA-1 with the
catalytic core via the Cys 56 residue. Finally, as found
for the native protein, DIBA-1 did not aﬀect the
DNA-binding step of the C56S, C65S and C56S-C65S
mutants, regardless of the cofactor context (data not
shown).
DISCUSSION
We have characterized the cooperative DNA-binding
property of HIV-1 IN to understand the structural deter-
minants of the reaction speciﬁcity at the DNA binding
level. To date, only the central catalytic domain was
clearly shown to be directly involved in the speciﬁc recog-
nition of the viral DNA substrate (12,43,44), although no
signiﬁcant diﬀerence in terms of aﬃnity between cognate
and non-speciﬁc random sequences can be evidenced in
most current DNA binding assays. Consistently, muta-
tions of some residues, known to be involved in such
speciﬁc contacts and essential for activity—for instance,
the Q148 or Y143 residue—do not dramatically alter the
formation of IN–DNA complexes (12,22,23). In this
study, we show that the IN N-terminal domain, contain-
ing a pseudo zinc ﬁnger, plays also a key role, at least
indirectly, for the formation of speciﬁc IN–DNA
contacts. The HHCC motif mediates a cooperative
DNA binding that occurs only in the presence of the
cognate viral sequence and the physiologically relevant
Mg
2+ cofactor. Furthermore, we found that DIBA-1, a
zinc ejector compound, induced a signiﬁcant decrease in
cooperativity, dependent on the ejection of zinc from the
N-terminal HHCC motif and, concomitantly, severely
impaired the 30-processing activity. However, our results
indicate a second mode of action of DIBA-1 for inhibiting
catalytic activity that is independent of zinc ejection but
requires a direct interaction with the central domain. This
second mechanism explains why DIBA-1 retained the
ability to inhibit the Mn
2+-dependent activity—even
though less eﬃciently compared to Mg
2+-dependent
activity—since the Mn
2+-dependent DNA binding was
principally non-cooperative. Although DIBA-1 covalently
targets both the N-terminal and the central domains,
regardless of the metallic cofactor (Mg
2+ or Mn
2+), the
relative contribution of each mechanism to the inhibition
of catalytic activity depends on the metallic cofactor ini-
tially bound to IN. Taken together, our data indicate that
the cooperative assembly of IN/DNA complexes is impor-
tant for the Mg
2+-dependent activity, but dispensable in
the Mn
2+ context. The DIBA-1-dependent zinc ejection
from the HHCC motif is responsible for the reduction of
cooperativity and the potent inhibitory eﬀect of DIBA-1
in Mg
2+ mainly originates in this process. The weaker
inhibition observed in the Mn
2+ context is not related
to a reduction of cooperativity but, most likely, to the
Cys 56 modiﬁcation in the central domain.
The cooperative DNA-binding of IN is related to a
speciﬁc DNA-binding mode
The weaker cooperativity index for DNA binding in the
presence of Mn
2+ compared to Mg
2+, as well as the more
potent DIBA-mediated inhibition of IN catalytic activity
in Mg
2+ compared to Mn
2+ (that originates in the
DIBA-induced loss of cooperativity in Mg
2+) conﬁrm
that the structural determinants for IN activity diﬀer
depending on the nature of the cofactor. It is well
known that the Mg
2+-dependent activity is more stringent
and predictive of physiological activity than Mn
2+-depen-
dent activity, e.g. for resistance mutations to anti-IN com-
pounds (45). Moreover, several functional mutations,
including those in the zinc-ﬁnger motif, yield
non-infectious particles and abolish Mg
2+-dependent
30-processing in vitro, whereas Mn
2+-dependent
30-processing and disintegration reactions are relatively
insensitive to the same mutations (30,46,47). Consistent
with this diﬀerential eﬀect, it has been shown that zinc
stimulates Mg
2+-dependent, but not Mn
2+-dependent,
reaction in preparations initially depleted in zinc (48).
It is then generally admitted that the zinc-ﬁnger motif
does not directly mediate the catalytic process but regu-
lates the speciﬁcity of the reaction via protein–protein
interactions and facilitating IN oligomerization (27–
29,49). Moreover, zinc stimulates dimerization of free
monomeric IN in Mg
2+ but not Mn
2+ solution in the
presence of detergent (27). Here, we found that the
DNA binding of IN is cooperative, characterized by a
Hill coeﬃcient of 2, in agreement with previous results
(18). Interestingly, this cooperativity was only observed
with Mg
2+ and signiﬁcantly reduced with Mn
2+, suggest-
ing that Mg
2+ and Mn
2+ mediate distinct mechanisms of
IN-DNA assembly. According to the role of the zinc
ﬁnger in the multimerization process and the
zinc-mediated stimulation of catalysis only in the Mg
2+
context, we suggest a relationship between the zinc ﬁnger
and the cooperative DNA-binding mode observed in the
presence of Mg
2+. Indeed, zinc ejection by DIBA-1 or
deletion of the N-terminal domain, signiﬁcantly decrease
the Hill coeﬃcient (Table 4). As suggested by a previous
work showing that point mutations in the zinc-ﬁnger
motif do not inﬂuence activity in Mn
2+ (30), zinc
Table 5. IC50 values characterizing IN inhibition (30-processing
reaction) by DIBA-1 obtained with diﬀerent cysteine mutants
a
Metallic
cofactor
b
IC50,n M
C280S C65S, C280S C56S, C280S C56S, C65S,
C280S
Mg
2+ 14±3 12±2 19±4 24±5
Mn
2+ 126±16 116±13 1155±547 566±186
aIN activity was measured as described in ‘Materials and Methods’
section with preincubation conditions corresponding to protocol 3.
b10mM.
Nucleic Acids Research, 2010,Vol.38, No. 11 3703ejection by DIBA-1 should also be neutral for Mn
2+-
dependent activity. However, the secondary binding site
in the catalytic core (C56) explains why IN is inhibited by
DIBA-1 in the presence of Mn
2+ and, consequently, why
the inhibitory eﬀects of DIBA-1 do not strictly mimic the
mutations in the zinc ﬁnger motif. Accordingly, the diﬀer-
ence between IC50 values measured in the presence of
Mg
2+ or Mn
2+ was even more pronounced in the
context of the C56S mutation (Table 5). Therefore, the
Cys 56 residue in the CC domain mainly mediates the
inhibition by DIBA-1 of the full-length IN in the Mn
2+
context (obviously, this residue fully accounts for the inhi-
bition of CC and N truncated proteins in the disintegra-
tion assay). In contrast, the inhibition of the Mg
2+-
dependent activity is weakly or not sensitive to the C56S
mutation, indicating that zinc ejection and the subsequent
loss of cooperativity lead to more dramatic eﬀects for
catalysis under Mg
2+ condition, minimizing the impact
of the C56S mutation and explaining the better IN inhi-
bition in the presence of Mg
2+ compared to Mn
2+.
Taking into account that Mg
2+ displays more reaction
speciﬁcity than Mn
2+, our data indicate a relationship
between the cooperative assembly of IN onto the DNA
substrate and the reaction speciﬁcity. Indeed, Mg
2+-
dependent DNA-binding is cooperative with the cognate
U5 DNA sequence but not with random DNA sequences.
Therefore, a speciﬁc conformation of IN, compatible with
a cooperative DNA-binding mode, only occurs or is
strongly favoured onto the cognate sequence in the
presence of Mg
2+. Consequently, the dimeric forms
responsible for 30-processing activity (2,3,5) could have
structural diﬀerences upon Mn
2+ or Mg
2+ binding.
Alternatively, Mn
2+ may also allow IN monomers to
perform 30-processing—hypothesis compatible with the
low Hill coeﬃcient obtained in the presence of Mn
2+—
but complementation experiments in Mn
2+ with individ-
ually inactive INs (49,50), as well as recent ﬁndings that
monomeric IN can dimerize upon incubation with viral or
random short oligonucleotides in the presence of Mn
2+
(51), suggest that Mn
2+-bound IN is also active as a
multimer. Consistently, we found similar long rotational
correlation times, characterizing the following complexes:
IN-Mg
2+-viral sequence, IN-Mn
2+-viral sequence and
IN-Mg
2+-random sequence. All y25 C values ( 39–44ns)
are compatible with a dimeric HIV-1 IN bound to DNA.
Altogether, our data suggest that the nature of the dimer
interface or the mechanism of dimerization, but not the
oligomeric status itself, is dependent on the DNA
sequence and the cofactor. Regarding the inﬂuence of
the DNA sequence, our data are in excellent agreement
with recent results of Lesbats et al. (51) who also found
that both viral and random sequences induce IN
dimerization, but the nature of the dimer diﬀers depending
on the DNA sequence. The authors have proposed a dif-
ference in the dimeric organization of IN in terms of
symmetry, with direct consequences for the
tetramerization process and competency of the formed
tetramer involved in the full-site integration reaction.
We have shown that the cooperative DNA-binding
mode strongly depends on the cofactor context and
appears to be primarily mediated by the N-terminal
domain. This however raises the question of how the
nature of the cofactor bound to the central domain
diﬀerentially aﬀects structural properties of the
N-terminal domain? It was previously described that
cofactor binding in the catalytic core can aﬀect by
long-distance eﬀect the conformations of both the N-
and C-terminal domains (52,53). A diﬀerential eﬀect of
Mg
2+/Mn
2+ on such conformational changes, could
explain the observed diﬀerences in the cooperative eﬀects
mediated by the N-terminal domain as a function of the
cofactor context. The diﬀerential behavior of IN between
the Mg
2+- and the Mn
2+-dependent catalysis, in terms of
speciﬁcity (with Mg
2+ leading to more stringent condi-
tions for catalysis), can be explained by a diﬀerent confor-
mation or plasticity of the active site, depending on the
nature of the metallic cofactor which is coordinated, in
relationship with the Pearson Hard-Soft Acid-Base
(HSBA) theory. Hard metal ions such as Mg
2+ (with a
small ionic radius and a d
0 electron conﬁguration) are
characterized by electron clouds which are not easily
deformed, in contrast to soft metal ions such as Mn
2+,
with a direct consequence on the dynamics of the active
site or/and the nature of the IN–DNA interaction. The
transmission of the long-distance eﬀect from the CC to
the N-terminal domain could be ensured by a trans
HHCC–catalytic core interaction (42) and, such a trans-
mission could be also diﬀerentially aﬀected by the nature
of the cofactor bound in the active site. From this point of
view, only Mg
2+ is compatible with cooperativity as the
presence of Mn
2+ or the absence of cofactor lead to
similar low Hill coeﬃcients (Table 4). Note that, we also
observed another long-distance eﬀect: the nature of the
cofactor also inﬂuenced the ability of the C-terminal
domain to aﬀect the overall aﬃnity of the IN–DNA
complex. The apparent aﬃnities for DNA were similar
for the full-length and C proteins in Mn
2+, but C
showed a lower aﬃnity in Mg
2+, reinforcing the idea
that the Mn
2+ context is less stringent than Mg
2+. This
result conﬁrms the importance of the C-terminal domain
in the correct positioning of the DNA substrate in the
active site of IN, compatible with speciﬁc catalysis (54).
Surprisingly, the recent X-ray structures of the PFV-1 IN
in complex with a pre-processed viral DNA end, obtained
in the presence of either Mg
2+ or Mn
2+, do not show any
metal-dependent structural diﬀerence in the organization
of the active site (7), suggesting that diﬀerential eﬀects of
metal cations on the structure/dynamics of IN only occur
prior to 30-processing catalysis.
Structural relationship between the N-terminal domain of
HIV-1 IN and the cooperative/speciﬁc DNA-binding mode
We found that the N-terminal domain, via the zinc-ﬁnger
motif, is responsible for the cooperative DNA binding and
thus plays a crucial role to form a speciﬁc IN-Mg
2+/DNA
complex, as the cooperative DNA-binding mode strictly
requires the cognate viral sequence, Mg
2+ as a cofactor
and zinc as a positive allosteric eﬀector. What is the role of
the N-terminal domain in the formation of the speciﬁc
complex?
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domain of HIV-1 IN is not essential for protein–viral
DNA contacts. Indeed, in the present study, we found
that the deletion of the N-terminal domain was not
dramatic in terms of overall aﬃnity. Thus, the role of
the N-terminal domain could be only indirect, via
protein–protein interaction, consistent with the eﬀect of
zinc on the multimerization process. The nature of the
protein–protein interactions involving the N-terminal
domain remains to be elucidated. Based on structural
data, the formation of a dimeric, 3’-processing form of
IN depends primarily on the CC (persistently dimeric
whatever the structure) and possibly on the N-terminal
domain (7,55,56). In contrast to the C-terminal domain
in the structure of the CC/C-terminal double-domain,
the N-terminal domains remains dimeric in the context
of the N-terminal/CC double-domain (55,56), although
with a diﬀerent interface compared to the isolated
domain (57). In this case, the cooperative eﬀect could
be mediated by a N-terminal/N-terminal interaction.
However, two recent and independent structural studies
indicate that the nature of this interaction is uncertain
for HIV-1(2) IN in the presence of the Lens epithelium
growth factor (LEDGF/p75) (58,59), suggesting that the
N-terminal/N-terminal interaction is weak and maybe not
physiologically relevant. It has been previously suggested
that IN oligomerization requires the interaction between
the N-terminal and the CC domains, with the catalytic
domain of one protomer which functions in trans with
the N-terminal domain of another protomer (42), suggest-
ing that the role of the N-terminal domain and its
zinc-ﬁnger motif in the multimerization process does not
necessarily imply a N-terminal/N-terminal interaction.
The structure of the multimeric full-length PFV-1 IN
conﬁrms this statement (7). According to structural and
biochemical data, the zinc-dependent and cooperative
assembly should be then related to a trans N-terminal/
catalytic core interaction. Interestingly, this trans interac-
tion, previously evidenced by using a N-ethylmaleimide-
modiﬁed IN (42), involves the HHCC motif and the Cys
56 residue (see below). Finally, it is important to note that
a role of zinc in the dimerization process does not exclude
an additional role in promoting tetramerization (28,29).
Indeed, the tetrameric model (i.e. dimer of dimer) of
HIV-1 IN proposed by Wang et al. (55) shows the zinc
coordination region of the N-terminal domain of one
dimer interacting with the catalytic core of the other
dimer. The role of the N-terminal domain in the stabiliza-
tion of the tetramer is also evidenced in the structure of
the PFV-1 IN (7).
Alternatively, the Lys14 residue was recently shown by
Zhao et al. (60) to be important for interactions with viral
DNA, suggesting that the N-terminal domain could be
directly involved in the assembly of the IN–viral DNA
complex. Moreover, the N-terminal region that contains
Lys14 is directly aﬀected by conformational metal-
induced changes (52), suggesting that this region could
be crucial for establishing speciﬁc IN–viral DNA
contacts and mediating the diﬀerential eﬀects of Mg
2+
and Mn
2+. Thus, it is not excluded that the HIV-1 IN
N-terminal domain could play a direct and pivotal role
in the relationship between the cooperative IN assembly
and the reaction speciﬁcity, by directly interacting with the
viral DNA sequence. Importantly, the X-ray structure of
PFV-1 IN bound to a viral DNA end highlights that the
N-terminal domain is involved in interaction with DNA,
together with the central and the C-terminal domains (7).
Insight into the mechanism of action of the DIBA-1
compound
DIBA-1 eﬃciently ejects the zinc from the N-terminal
domain of IN, as shown by VIS-spectrophotometry, and
eﬃciently inhibits IN 30-processing activity. We found that
the zinc-ﬁnger motif (HHC
40C
43) was a particularly
important target for DIBA-1, as shown by mass
spectrometry, and probably accounts for the loss of the
Mg
2+-mediated cooperativity induced by zinc ejection.
However, using truncated INs that require Mn
2+ to
mediate the disintegration reaction (11), we found that
DIBA-1 could still inhibit CC and N, indicating an addi-
tional eﬀect of DIBA-1, i.e. DIBA-1 can also directly
aﬀects the catalytic site, independent of zinc ejection. Of
the three Cys residues in the catalytic core, Cys 56, Cys 65
and Cys 130, mass spectrometry and site-directed
mutagenesis indicated that Cys 56 was actually the
DIBA-1 target. Indeed, the C65S mutant remained sensi-
tive to DIBA-1 while C56S and C56S/C65S mutants were
much less aﬀected by DIBA-1 (this diﬀerence was only
observed in the Mn
2+ context). Altogether, our results
show that the covalent binding of DIBA-1 to Cys 56
probably perturbs the integrity of the active site, as
found by others with the N-ethylmaleimide modiﬁcation
(42), with a direct inhibitory eﬀect of the catalysis. The
Cys 56 residue is not essential for catalysis by itself since
the C56S mutant exhibits a wild-type activity.
Nevertheless, its covalent modiﬁcation—which does not
prevent DNA binding—probably blocks the active site
into an inactive state. This eﬀect is clearly diﬀerent from
the one previously observed with the modiﬁcation of Cys
65 by mercaptosalicylhydrazide derivatives which eﬃ-
ciently inhibit IN binding to viral DNA (61). This is con-
sistent with the location of the Cys 65 residue in the active
site which is closer to the catalytic triad and the donor site
compared to Cys 56.
In conclusion, DIBA-1 covalently targets both the
HHCC motif in the N-terminal domain and Cys 56 in
the active site. DIBA-1 binds to each target cysteine
(C40, C43, C56) as a monomer (Figure 6E), consistent
with the reaction mechanism proposed by by Loo et al.
(41). Therefore, two DIBA-1 molecules are involved in the
reaction with IN. Accordingly, we found that zinc ejection
coincides with the reaction of two DIBA-1 molecules per
IN protomer, even though only one, which targets the
HHCC motif, would be suﬃcient for zinc ejection, the
second one being trapped in the active site. It was
previously suggested a trans interaction between the
HHCC motif domain and the N-ethylmaleimide-sensitive
site (involving Cys 56) (42). As the HHCC motif and the
Cys 56 residue are both targeted by DIBA-1, some
synergistic eﬀects between the two sites could be
expected regarding the overall DIBA-1-mediated
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Mg
2+-dependent inhibition is uncertain as DIBA-1
showed similar IC50 values in Mg
2+ for the C56S, C65S
and C56S/C65S mutants. Thus, the interdependency of
the two mechanisms in the overall inhibition remains
unclear. Taking into account that (i) the integrity of the
HHCC motif is dispensable in the Mn
2+ context and the
Mn
2+-dependent activity is then primarily aﬀected by the
covalent modiﬁcation of the Cys 56 residue, (ii) the inhi-
bition of the Mg
2+-dependent activity by DIBA-1 is only
slightly inﬂuenced by the mutation of the Cys 56 residue
(with the zinc ejection process which fully accounts for the
inhibition in Mg
2+), our results suggest that the relative
impact of the two mechanisms of inhibition strongly
depends on the cofactor initially bound to IN, and it is
unlikely that these two mechanisms occur simultaneously
in a given cofactor context.
Many IN inhibitors show diﬀerent eﬃcacy in vitro
depending on the metallic cofactor used, putatively
because of diﬀerent chelation eﬀects in the active site
between Mg
2+ and Mn
2+ (61–63). Here, the extent of
30-processing inhibition by DIBA-1 was also strongly
dependent on the cofactor. The modest eﬀect of the
C56S mutation on inhibition in the Mg
2+ compared to
the Mn
2+ context also suggests a diﬀerential chelation
eﬀect in the active site. Although we did not ﬁnd signiﬁ-
cant complexation between DIBA-1 and Mn
2+ prior to
IN binding under our experimental conditions, it is not
excluded that such a complexation may occur with Mn
2+,
but not with Mg
2+, in the active site context for proximity
reasons, based on a recent study on complexes involving
bis(2-bromophenyl)disulﬁde and transition metals (39).
However, DIBA-1 was clearly and reproducibly a better
inhibitor in the context of Mg
2+ than Mn
2+, suggesting
that the diﬀerential eﬀect originates mainly in the zinc
ejection which can be considered as the most potent inhi-
bition mechanism. Therefore, DIBA-1-dependent zinc
ejection (this study) or the presence of a point mutation
in the zinc-ﬁnger motif (30) leads to a severe catalytic
defect with Mg
2+ as a cofactor. Finally, whatever the
mechanism, DIBA-1 inhibits 30-processing although it
does not perturb the overall aﬃnity of IN for the DNA
substrate. This property is clearly diﬀerent than the two
main anti-IN families of small molecules. INBIs inhibit
30-processing, but competitively prevent the binding of
IN to viral DNA (18). INSTIs cannot ﬁt in the active
site of the free IN and do not prevent the binding of the
viral DNA (19). Instead, they selectively target the IN–
viral DNA complex and, consequently, inhibit the strand
transfer reaction (20). INSTIs are not or poorly eﬃcient
against 30-processing. Here, DIBA-1 blocks catalytic
30-processing (6¼INSTI) at a post-DNA-binding step
(6¼INBI).
CONCLUSION
The overall aﬃnities of IN for diﬀerent sequences are gen-
erally similar suggesting that IN could not discern between
the cognate viral DNA sequence and a random sequence
at the DNA binding level. However, this study shows that
the corresponding cooperative DNA-binding properties
are distinct. The factors/parameters that modulate the
Hill coeﬃcient—i.e. the nature of the DNA sequence,
the nature of the metallic cofactor, the presence of
zinc—probably aﬀect IN-DNA complexes in terms of
protein-protein interface or/and IN positioning on the
DNA substrate, with direct consequences on the establish-
ment of speciﬁc protein/DNA contacts rather than by
changing binding free energy. DIBA-1 was discovered by
a screening program (National Cancer Institute) as eﬀec-
tive against HIV-1 and targeting retroviral NCp7 protein
(31–33). Our data suggest that DIBA-1 may also targets
retroviral IN. Although DIBA compounds have issues
with selectivity/toxicity and bioavailability (33), our
results reinforce the importance of developing anti-IN
compounds with alternative non-competitive mechanisms.
Compounds targeting the IN oligomerization process or
acting as allosteric compounds—with diﬀerent mecha-
nisms of action compared to INBIs or INSTIs—could
be eﬀective without causing cross-resistance to INBI or
INSTI compounds (64,65). Recently, peptides that
modulate the IN oligomerization process were identiﬁed
and called ‘shiftides’ (65–67). This promising approach
requires a deeper understanding of the role of the diﬀerent
IN domains in the oligomerization process, taking into
consideration the cofactor context, because it is
well-established that using Mg
2+ as a cofactor is a
better predictor of anti-IN activity than using Mn
2+
(45,68). Accordingly, the present study demonstrates
that the mechanism of IN/DNA recognition signiﬁcantly
diﬀers depending on the cofactor context.
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